HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.3, Iss.11, 2008-11, pp. : 1363-1369

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics

Current Medicinal Chemistry, Vol. 18, Iss. 11, 2011-04 ,pp. : 1658-1671

Bentham Science Publishers

Access to resources Recommend Favorite

Pertuzumab: In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer

By Keating Gillian M.

Drugs, Vol. 72, Iss. 3, 2012-02 ,pp. : 353-360

Adis International

Access to resources Recommend Favorite

Development of PARP inhibitors in oncology

By Rodon Jordi Iniesta Maria D Papadopoulos Kyriakos

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 1, 2009-01 ,pp. : 31-43

Informa Healthcare

Access to resources Recommend Favorite

Farnesyltransferase Inhibitor as Anticancer Agent

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 6, 2009-01 ,pp. : 638-652

Bentham Science Publishers

Access to resources Recommend Favorite

Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing

Current Medicinal Chemistry, Vol. 20, Iss. 10, 2013-04 ,pp. : 1203-1217

Bentham Science Publishers

Access to resources Recommend Favorite